Neurotech Pharmaceuticals

Focus: Neurotech Pharmaceuticals specializes in encapsulated cell therapy with a focus on neurology and gene therapy applications. The company is a mid-stage biotech developer headquartered in Cumberland, Rhode Island with a lean pipeline across retinal diseases, neurological disorders, and neurovascular devices.

Neurology Gene Therapy Cell Therapy

Profile data last refreshed 2h ago · AI intelligence enriched 2w ago

Open Jobs

Should You Work at Neurotech Pharmaceuticals?

AI assessment

Early-stage cell therapy play with rare Phase 4 catalyst potential, but only pursue if comfortable with high uncertainty on financial viability and organizational maturity.

Why Work Here

Lead a cutting-edge cell therapy platform (encapsulated cell therapy) in high-unmet-need retinal indications with NT-501 in Phase 3 for MacTel and Phase 4 post-approval follow-up.

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Late-stage

5 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Intracranial stent for wide-necked aneurysms

Brain Diseases

N/A

Clinical Trials (1)

NCT06189950Registration Trial of the Intracranial Visualized Stent for the Wide-necked Intracranial Aneurysms:REBRIDGE

N/A

Help build intelligence for Neurotech Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to a diversified pipeline spanning 18 active trials across retinal dystrophies, autism (NTI164 Phase 3), and neurovascular devices—broad therapeutic area exposure.

Rare commercial opportunity: NT-501/revakinagene taroretcel-lwey advanced to Phase 4, signaling near-term revenue potential in an orphan/rare disease market.

Watch Out For

Severe opacity on company scale and funding: no employee count, founding date, or revenue data disclosed; only 2 active job openings suggest small, potentially cash-constrained organization.
Pipeline breadth without depth—portfolio spans retinal implants, psychiatric (autism), neurovascular devices, and neuromodulation with no clear focus, increasing execution risk and diluting R&D spend.
No published research output (0 publications on record) and minimal public visibility; difficult to assess scientific credibility or competitive differentiation in a crowded cell-therapy space.

Generated by Claude from Neurotech Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Motif XCS System

Major Depressive Disorder

N/A

Clinical Trials (2)

NCT07594483Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium

N/A

NCT07684794Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium - Maintenance

N/A

Pascal device

Post-Acute COVID-19 Syndrome

N/A

Clinical Trials (1)

NCT06739668Humanity Neurotech Device Clinical Trial in Adults With Long COVID Cognitive Dysfunction

N/A

Rapamycin neurovascular Balloon Catheter

Cerebral Atherosclerotic Stenosis

N/A

Clinical Trials (1)

NCT06683118Registration Trial of the Drug-coated Balloon for the Symptomatic Cerebral Atherosclerotic Stenosis

N/A

DSF-rTMS

Fibromyalgia

N/A

Clinical Trials (1)

NCT01229852Treatment of Fibromyalgia Using Deep Shaped-Field Transcranial Magnetic Stimulation a Clinical Feasibility Study

N/A

Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator

Major Depressive Disorder

N/A

Clinical Trials (1)

NCT01431001Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression

N/A

Intracranial Distal Access Catheter

Acute Ischemic Stroke

N/A

Clinical Trials (1)

NCT06989931Intracranial Distal Access Catheter in Neurointerventional Therapy

N/A

INTENT Neural Interface System

Tetraplegia/Tetraparesis

N/A

Clinical Trials (1)

NCT07521930Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)

N/A

Microport NeuroTech Tubridge Plus flow-diverter Stent

Intracranial Aneurysm

N/A

Clinical Trials (1)

NCT05898893PARAT PLUS (The Tubridge Plus For The Treatment Of Wide-Necked Intracranial Aneurysms)

N/A

Intracranial stent for wide-necked aneurysms

Brain Diseases

N/A

Clinical Trials (1)

NCT05275296Registration Trial of the Intracranial Visualized Stent for the Wide-necked Intracranial Aneurysms

N/A

Endovascular treatment

Intracranial Aneurysm

N/A

Clinical Trials (1)

NCT05646108Tubridge Flow Diverter Study For Intracranial Aneurysms

N/A

Coil Embolization System

Intracranial Aneurysm

N/A

Clinical Trials (1)

NCT02990156CATCH [Short Name for: Coil Application Trial in China]

N/A

Bridge

Brain Diseases

N/A

Clinical Trials (1)

NCT06186024A PROSPECTIVE, MULTICENTER, SINGLE-ARM TRIAL FOR THE NEW SIZES OF BRIDGE STENTS FOR VERTEBRAL ARTERY STENOSIS: Bridge-MAX

N/A

Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator

Depressive Disorder, Major

N/A

Clinical Trials (1)

NCT01909232A Clinical Trial for the Treatment of Depression With Repetitive Transcranial Magnetic Stimulation (rTMS)

N/A

Tubridge

Brain Diseases

N/A

Clinical Trials (1)

NCT05829746PROSPECTIVE, MULTI-CENTER, OPEN-LABEL, SINGLE-ARM REGISTRATION TRIAL OF THE TUBRIDGE FOR THE TREATMENT OF WIDE-NECKED SMALL AND MEDIUM-SIZED INTRACRANIAL ANEURYSMS

N/A

Endoscopic surgery

Intracerebral Hemorrhage

N/A

Clinical Trials (1)

NCT06843616A PILOT TRIAL of a DISPOSABLE INTRACEREBRAL ASPIRATION ENDOSCOPE for the TREATMENT of INTRACEREBRAL HEMATOMA（FAST-HET）

N/A

liquid embolic agent

Brain Arteriovenous Malformation

N/A

Clinical Trials (1)

NCT07314047The Liquid Embolic Agent for the Treatment of Brain Arteriovenous Malformation

N/A

Numen SILK coil embolization system

Chronic Subdural Hemorrhage (cSDH)

N/A

Clinical Trials (1)

NCT07197840The CHALLENGER Registry

N/A

Nufairy® Coil embolization system for intracranial aneurysm

Intracranial Aneurysm

N/A

Clinical Trials (1)

NCT06466564Bioabsorbable/Nufairy Coil Application Trial in China

N/A

NTI164

Healthy

Phase 1

Clinical Trials (1)

NCT06713447NTI164 Human PK Study

Phase 1

NT-501 implant

Idiopathic Juxtafoveal Telangiectasia

Phase 1

Clinical Trials (1)

NCT01327911Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)

Phase 1

NT-503-3 ECT implantation

Macular Degeneration

Phase 1/2

Clinical Trials (1)

NCT02228304Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Phase 1/2

NTI164

Rett Syndrome

Phase 1/2

Clinical Trials (1)

NCT06621043Assessing the Safety and Efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) in the Treatment of Rett Syndrome (RTT)

Phase 1/2

FEN164

Autism Spectrum Disorder

Phase 1/2

Clinical Trials (1)

NCT05516407Safety and Efficacy of Oral Full-Spectrum Medicinal Cannabis Plant Extract in Children With Autism Spectrum Disorder.

Phase 1/2

NTI164

PANS Pediatric Acute-Onset Neuropsychiatric Syndrome

Phase 1/2

Clinical Trials (1)

NCT06621888Investigating The Effects Of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) On Paediatric Acute-onset Neuropsychiatric Syndrome (PANS)

Phase 1/2

Ciliary neurotrophic factor

MacTel (Macular Telangiectasia) Type 2

Phase 2

Clinical Trials (1)

NCT03071965Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel)

Phase 2

NT-501

Retinitis Pigmentosa

Phase 2

Clinical Trials (1)

NCT01530659Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa

Phase 2

NT-501

Retinitis Pigmentosa

Phase 2

Clinical Trials (1)

NCT00447980A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa

Phase 2

Ciliary neurotrophic factor

Macular Telangiectasia Type 2

Phase 2

Clinical Trials (1)

NCT01949324A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel

Phase 2

High Dose NT-501 implant

Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Intermediate Dry Stage

Phase 2

Clinical Trials (1)

NCT00447954A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration

Phase 2

NT-501 CNTF implant

Macular Telangiectasia Type 2

Phase 2

Clinical Trials (1)

NCT04729972Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2

Phase 2

Low Dose NT-501

Retinitis Pigmentosa

Phase 2

Clinical Trials (1)

NCT00447993A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa

Phase 2

NTI164

RETT Syndrome With Proven MECP2 Mutation

Phase 2/3

Clinical Trials (1)

NCT07257978Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome

Phase 2/3

NTI164

Autism Spectrum Disorder

Phase 2/3

Clinical Trials (1)

NCT05626959Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder

Phase 2/3

NT-501

Macular Telangiectasia Type 2

Phase 3

Clinical Trials (1)

NCT03319849A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B

Phase 3

NTI164

Autism

Phase 3

Clinical Trials (1)

NCT07257939NTI164 in Autism Spectrum Disorder

Phase 3

NT-501 CNTF Implant

Macular Telangiectasia Type 2

Phase 3

Clinical Trials (1)

NCT06397131A Study to Determine the Safety and Efficacy of NT-501 With M-CHFM

Phase 3

Experimental Device A, a self-expanding rapamycin target-eluting stent

Intracranial Arteriosclerosis

Phase 3

Clinical Trials (1)

NCT06925971A Randomized Trial of the Rapamycin Target Eluting Stent for the Treatment of Symptomatic Cerebral Artery Atherosclerotic Disease（TARGET-DREAM）

Phase 3

NT-501

Macular Telangiectasia Type 2 (MacTel)

Phase 3

Clinical Trials (1)

NCT03316300A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A

Phase 3

NT-501/revakinagene taroretcel-lwey

Macular Telangiectasia Type 2 (MacTel)

Phase 4

Clinical Trials (1)

NCT06971939Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants